CYTIVA

History

Year	Detail
1968	Cytiva, formerly GE Healthcare Life Sciences, was founded in 1968. In 2020, the company was acquired by Danaher Corp. and renamed Cytiva.
2020	The company partnered with Takara Bio to manufacture a DNA vaccine candidate for COVID-19.
2020	The company collaborated with Entos Pharmaceuticals to enable GMP production of the Fusogenix protein component, which facilitates intracellular DNA delivery for COVID-19 vaccines.
2020	The company entered into a technology investment agreement with the Biomedical Advanced Research and Development Authority (BARDA) to increase manufacturing capacity for single-use consumables and hardware at the Massachusetts facilities and Logan, Utah site.
2020	The company collaborated with 4Tune Engineering, a manufacturing sciences and technology provider, to include 4Tune Engineering’s iRISK platform in Cytiva’s cell therapy product offering.
2021	Cytiva acquired Vanrx Pharmasystems, a Canadian aseptic filling innovator, to provide customers and the market with "idea to injection" solutions.
2021	Cytiva and Multiply Labs collaborated to develop a robotic manufacturing system that automates the manual portions of the cell therapy manufacturing workflow.
2021	The company acquired the German scientific software maker GoSilico to strengthen digital capabilities in bioprocessing.
2021	The company acquired Intermountain Life Sciences, a manufacturer of high-purity water, to double the capacity for buffers and liquid cell culture media.
2021	Cytiva entered into a cooperative agreement with the Department of Defense, in coordination with the Department of Health and Human Services (HHS), to support expanding its chromatography manufacturing operations to the U.S.
2022	The company collaborated with Nucleus Biologics to accelerate the development of custom cell media for cell and gene therapies.
2022	The company collaborated with NecstGen, a non-profit contract development and manufacturing organization, to accelerate the development of cell and gene therapies.
2022	ForecyteBio, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), collaborated with the company to accelerate the development and manufacturing of CGTs.
2022	Culture Biosciences and Cytiva partnered to innovate in upstream bioprocessing to advance the development and manufacturing of new therapies.
2023	Cytiva and RoosterBio, Inc. collaborated to develop a mass purification process to manufacture exosomes.
2024	The company partnered with LevitasBio to deliver an innovative single-cell workflow for genomics researchers in academia and industry.
2024	Cytiva opened its first Innovation Hub in Korea in the Songdo Bio-cluster in Incheon. The new facility is intended to advance biopharmaceutical manufacturing and meet the evolving needs of Cytiva customers in Korea and the wider APAC region.